Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.65 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.64 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.64 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.64 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.64 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.64 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.64 |
| ▸ | FLT3 | P36888 | 2/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404623 | 1.00 | ERBB2 (0.69) | ERBB2EGFRLRRK2PSEN1PSEN2 | |
| SCHEMBL8002163 | 0.96 | ERBB2 (0.64) | ERBB2EGFRLRRK2PSEN1PSEN2 | |
| SCHEMBL8002167 | 0.96 | ERBB2 (0.64) | ERBB2EGFRLRRK2PSEN1PSEN2 | |
| SCHEMBL6395558 | 0.88 | EGFR (0.62) | ERBB2EGFRLRRK2PSEN1PSEN2 | |
| SCHEMBL6395565 | 0.88 | EGFR (0.62) | ERBB2EGFRLRRK2PSEN1PSEN2 | |
| SCHEMBL6408143 | 0.88 | ERBB2 (0.69) | ERBB2FLT3MDM2 | |
| SCHEMBL6396491 | 0.88 | ERBB2 (0.69) | ERBB2FLT3MDM2 | |
| SCHEMBL6390048 | 0.87 | CCNE1 (0.58) | ERBB2EGFRPSEN1PSEN2APH1B | |
| SCHEMBL6391054 | 0.87 | PLK4 (0.62) | ERBB2EGFRLRRK2PSEN1PSEN2 | |
| SCHEMBL6391057 | 0.87 | PLK4 (0.62) | ERBB2EGFRLRRK2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | claimed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | claimed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | ERBB2 262/4885EGFR 867/4885LRRK2 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.